Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2018-10-01
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Sarcoid induced focal inflammation in myocardium should show high 18F-GE180 uptake. 18F-GE180 PET scans will give reliable data about inflammatory sarcoidosis activity in the myocardium. 18F-GE180 PET is expected to improve diagnostic accuracy compared to 18F-FDG-PET and/or contrast enhanced MRI.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-FDG-PET/MRI
18F-FDG-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-FDG
18F-GE180-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-GE180
18F-GE180-PET/MRI
18F-FDG-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-FDG
18F-GE180-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-GE180
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-FDG-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-FDG
18F-GE180-PET/MRI
Contrast-enhanced MRI scanning after injection of 18F-GE180
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lung department: Clinically verified lung and/or mediastinal sarcoidosis
Exclusion Criteria
* Treatment for sarcoidosis started
* Severe arrhythmia
* Patients with pacemakers or defibrillator
* Claustrophobia
* Known alcohol or drug abuse
* Kidney failure (eGFR \< 30)
* Weight \> 120 kg
* Diabetes Mellitus type I and II
* Patients that take immunosuppressive or immunomodulatory medication for any reason
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Norwegian University of Science and Technology
OTHER
University Hospital, Essen
OTHER
St. Olavs Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edmund Søvik
Role: STUDY_CHAIR
St. Olavs Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Olav University Hospital, Dept Radiology and Nuclear Medicine
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-000331-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2016/883
Identifier Type: -
Identifier Source: org_study_id